The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.
 
Wungki Park
Consulting or Advisory Role - Cerner Enviza; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Merck (Inst)
 
Catherine O'Connor
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Carly Schwartz
No Relationships to Disclose
 
Anna M. Varghese
Consulting or Advisory Role - Lilly (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Mary Larsen
No Relationships to Disclose
 
Fiyinfolu Balogun
Honoraria - Mediflix (I)
Patents, Royalties, Other Intellectual Property - Mission Driven Tech. Brachytherapy (I)
 
Robin Brenner
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
Erin Diguglielmo
No Relationships to Disclose
 
Shigeaki Umeda
No Relationships to Disclose
 
Elias Karnoub
No Relationships to Disclose
 
Fergus Keane
No Relationships to Disclose
 
Haochen Zhang
No Relationships to Disclose
 
Smita Suhas Joshi
No Relationships to Disclose
 
Nadeem Riaz
Honoraria - PeerView
Consulting or Advisory Role - Mirati Therapeutics; Repare Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Paige.AI; Pfizer; Repare Therapeutics
Travel, Accommodations, Expenses - Varian Medical Systems
 
David Paul Kelsen
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Christine A Iacobuzio-Donahue
Research Funding - Bristol Myers Squibb Foundation
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma